Accéder au contenu
Merck
Toutes les photos(1)

Documents

SML0120

Sigma-Aldrich

Perhexiline maleate salt

≥98% (HPLC)

Synonyme(s) :

2-(2,2-Dicyclohexylethyl)piperidine

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C19H35N · C4H4O4
Numéro CAS:
Poids moléculaire :
393.56
Numéro CE :
Numéro MDL:
Code UNSPSC :
12352200
ID de substance PubChem :
Nomenclature NACRES :
NA.25

Niveau de qualité

Pureté

≥98% (HPLC)

Forme

powder

Couleur

white to tan

Solubilité

DMSO: ≥5 mg/mL

Température de stockage

2-8°C

Chaîne SMILES 

OC(=O)\C=C/C(O)=O.C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3

InChI

1S/C19H35N.C4H4O4/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18;5-3(6)1-2-4(7)8/h16-20H,1-15H2;1-2H,(H,5,6)(H,7,8)/b;2-1-

Clé InChI

JDZOTSLZMQDFLG-BTJKTKAUSA-N

Informations sur le gène

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Perhexiline maleate regulates coronary vasodilatation and blocks exercise-induced tachycardia. It is used to treat angina pectoris and variant angina. Perhexiline maleate functions as a cardiac metabolic agent. It is associated with peripheral neuropathy, high intracranial pressure with papilledema and proximal myopathy.

Application

Perhexiline maleate salt has been used as a stock for worm lifespan assay. It has also been used to block fatty acid oxidation.
Perhexiline maleate salt has been used to block fatty acid oxidation. It has also been used as 5′ adenosine monophosphate-activated protein kinase (AMPK) activator and in worm lifespan assay.

Actions biochimiques/physiologiques

Perhexiline maleate is an anti-anginal metabolic modulator. It inhibits the mitochondrial enzyme carnitine palmitoyltransferase CPT-1 and to a lesser extent CPT-2. This causes a shift in myocardial substrate utilisation from long chain fatty acids to carbohydrates, resulting in increased glucose and lactate utilization and increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency. Perhexiline maleate was also recently found to inhibit the activity of mTORC1.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

B D Walker et al.
British journal of pharmacology, 127(1), 243-251 (1999-06-16)
Perhexiline has been used as an anti-anginal agent for over 25 years, and is known to cause QT prolongation and torsades de pointes. We hypothesized that the cellular basis for these effects was blockade of I(Kr). A stable transfection of
Raised intracranial pressure due to perhexiline maleate
Stephens WP, et al.
British Medical Journal, 1(6104), 21-21 (1978)
V Shacoori et al.
Research communications in chemical pathology and pharmacology, 59(2), 161-172 (1988-02-01)
Human clinical observations and in vivo studies have shown that the amphiphilic drug perhexiline maleate is responsible for lipidosis storage disorders. When the drug was incubated in vivo with rat brain homogenates, the ouabain-sensitive (Na+,K+)-ATPase and the Mg++-ATPase activities were
M A Mariscal et al.
Biochemical pharmacology, 37(18), 3461-3465 (1988-09-15)
The effect of the antianginal agent perhexiline maleate (160 mg/kg i.g., daily for 4 days) on the biliary excretion of sulfobromophthalein (BSP) and BSP-glutathione and the hepatic activity of glutathione S-transferases was investigated in Wistar rats. Perhexiline maleate caused a
B J Foster et al.
Cancer chemotherapy and pharmacology, 22(2), 147-152 (1988-01-01)
The clinical utility of adriamycin in the treatment of patients with metastatic breast cancer is often-limited by the development of drug resistance. It has been recognized that in addition to the development of primary resistance against adriamycin, malignant cells can

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique